At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALUR ALLURION TECHNOLOGIES
Post-Mkt 02-02 17:17:29 EST
1.24
-0.11
-8.15%
盘后1.24
+0.000.00%
16:05 EST
High1.39Low1.17Vol177.28K
Open1.35D1 Closing1.35Amplitude16.30%
Mkt Cap15.20MTradable Cap7.26MTotal Shares12.26M
T/O228.40KT/O Rate3.03%Tradable Shares5.86M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-US natgas companies
Reuters  ·  01-26
BUZZ-U.S. STOCKS ON THE MOVE-US natgas companies
Allurion Technologies files to sell 5.99M shares of common stock for holders
TIPRANKS  ·  01-10
Allurion Technologies files to sell 5.99M shares of common stock for holders
Allurion Technologies Holdings Inc. Held Annual Shareholder Meeting
Reuters  ·  2025-12-20
Allurion Technologies Holdings Inc. Held Annual Shareholder Meeting
BRIEF-Allurion Reports 23% Weight Loss, 14% Lean Mass Gain On Combining Program With Tirzepatide
Reuters  ·  2025-11-26
BRIEF-Allurion Reports 23% Weight Loss, 14% Lean Mass Gain On Combining Program With Tirzepatide
BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's
Reuters  ·  2025-11-25
BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's
Allurion reports initial results on Allurion Program, tirzepatide combination
TIPRANKS  ·  2025-11-25
Allurion reports initial results on Allurion Program, tirzepatide combination
Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy
Reuters  ·  2025-11-25
Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and Glp-1 Adherence
THOMSON REUTERS  ·  2025-11-25
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and Glp-1 Adherence
Allurion Technologies Inc - Average Weight Loss of 23% With 14% Increase in Lean Body Mass
THOMSON REUTERS  ·  2025-11-25
Allurion Technologies Inc - Average Weight Loss of 23% With 14% Increase in Lean Body Mass
Allurion Smart Capsule Delivers Superior Weight Loss and Body Composition in New Clinical Study
Reuters  ·  2025-11-20
Allurion Smart Capsule Delivers Superior Weight Loss and Body Composition in New Clinical Study
Allurion Technologies Is Maintained at Neutral by Chardan Capital
Dow Jones  ·  2025-11-20
Allurion Technologies Is Maintained at Neutral by Chardan Capital
Allurion Announces Strategic Distribution Partnership With Prosurg Medical In Brazil To Pioneer New Approach Focused On Metabolically Healthy Weight Loss
Reuters  ·  2025-11-20
Allurion Announces Strategic Distribution Partnership With Prosurg Medical In Brazil To Pioneer New Approach Focused On Metabolically Healthy Weight Loss
Allurion Technologies Signs Distribution Partnership with ProSurg Medical in Brazil
Reuters  ·  2025-11-18
Allurion Technologies Signs Distribution Partnership with ProSurg Medical in Brazil
Allurion Technologies Inc - Partnership to Increase Access to Allurion Program With Glp-1 Therapy
THOMSON REUTERS  ·  2025-11-18
Allurion Technologies Inc - Partnership to Increase Access to Allurion Program With Glp-1 Therapy
Allurion Technologies Delays Quarterly Financial Filing
Reuters  ·  2025-11-18
Allurion Technologies Delays Quarterly Financial Filing
Allurion Technologies Q3 revenue beats expectations
Reuters  ·  2025-11-12
Allurion Technologies Q3 revenue beats expectations
Allurion Technologies Q3 Adj. EPS $(1.18) Misses $(1.17) Estimate, Sales $2.658M Beat $2.350M Estimate
Benzinga  ·  2025-11-12
Allurion Technologies Q3 Adj. EPS $(1.18) Misses $(1.17) Estimate, Sales $2.658M Beat $2.350M Estimate
BRIEF-Allurion Technologies Q3 Revenue USD 2.658 Million
Reuters  ·  2025-11-12
BRIEF-Allurion Technologies Q3 Revenue USD 2.658 Million
Allurion Technologies Q3 Operating Expenses USD 10.934 Million
THOMSON REUTERS  ·  2025-11-12
Allurion Technologies Q3 Operating Expenses USD 10.934 Million
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  2025-11-12
Calendar of U.S. Earnings Expected in the Week Ahead

Introduction

Company Name.
ALLURION TECHNOLOGIES
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
Issue price:
--